SHWGY (Shandong Weigao Group Medical Polymer Co) EBIT: $321 Mil (TTM As of Dec. 2025)

What is Shandong Weigao Group Medical Polymer Co EBIT?

Shandong Weigao Group Medical Polymer Co SHWGY 70 EBIT is $321 Mil as of Dec. 2025. GuruFocus rates SHWGY with a GF Score™ of 70/100 and a GF Value™ of $3.17 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Shandong Weigao Group Medical Polymer Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $134 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $321 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shandong Weigao Group Medical Polymer Co's annualized ROC % for the quarter that ended in Dec. 2025 was 5.54%. Shandong Weigao Group Medical Polymer Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 14.69%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shandong Weigao Group Medical Polymer Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 23.18%.

Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shandong Weigao Group Medical Polymer Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	211.906 * ( 1 - 18.85% )	/	( (3088.97	+	3119.2)	/ 2 )
=	171.961719	/	3104.085
=	5.54 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5033.452	-	600.214	-	( 1344.268	-	max(0, 773.775	-	2883.439	+	1344.268	))
=	3088.97

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5118.143	-	656.859	-	( 1342.084	-	max(0, 776.974	-	2933.694	+	1342.084	))
=	3119.2

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Shandong Weigao Group Medical Polymer Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	268.25	/	( ( (1043.609 + max(718.431, 0))	+	(1068.974 + max(822.185, 0)) )	/	2 )
=	268.25	/	( ( 1762.04	+	1891.159 )	/	2 )
=	268.25	/	1826.5995
=	14.69 %

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(902.616	+	318.142	+	146.772)	-	(600.214	+	0	+	48.885)
=	718.431

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1111.269	+	357.092	+	60.030999999999)	-	(656.859	+	0	+	49.348)
=	822.185

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shandong Weigao Group Medical Polymer Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	321.117	/	1385.098
	=	23.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Weigao Group Medical Polymer Co EBIT Related Terms

Shandong Weigao Group Medical Polymer Co EBIT Historical Data

* Premium members only.

The historical data trend for Shandong Weigao Group Medical Polymer Co's EBIT can be seen below:

Shandong Weigao Group Medical Polymer Co EBIT Chart

Shandong Weigao Group Medical Polymer Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

473.88

513.09

370.04

385.03

324.76

Shandong Weigao Group Medical Polymer Co Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															145.04	206.10	179.68	186.99	134.13

SHWGY vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Weigao Group Medical Polymer Co EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Group Medical Polymer Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shandong Weigao Group Medical Polymer Co's EV-to-EBIT falls into.

Save Embed

70GF Score

Shandong Weigao Group Medical Polymer Co Ltd SHWGY

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Shandong Weigao Group Medical Polymer Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $321 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $321 Mil mean?

Shandong Weigao Group Medical Polymer Co (SHWGY) has a EBIT of $321 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Weigao Group Medical Polymer Co.

Is Shandong Weigao Group Medical Polymer Co's EBIT too high?

Shandong Weigao Group Medical Polymer Co's current EBIT is $321 Mil. Overall, Shandong Weigao Group Medical Polymer Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Shandong Weigao Group Medical Polymer Co's EBIT compare to ISRG and BDX?

Shandong Weigao Group Medical Polymer Co's EBIT of $321 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Weigao Group Medical Polymer Co. Shandong Weigao Group Medical Polymer Co's current EBIT is $321 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Shandong Weigao Group Medical Polymer Co stock overvalued right now?

Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co (SHWGY) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.17, compared to a current price of $1.58 — trading 50.2% below its estimated fair value. The current EBIT is $321 Mil. Shandong Weigao Group Medical Polymer Co's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Shandong Weigao Group Medical Polymer Co (SHWGY), the current EBIT is $321 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Weigao Group Medical Polymer Co (SHWGY) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co stock appears to be undervalued. The current stock price of $1.58 is trading 50.2% below its estimated GF Value™ of $3.17. GuruFocus considers Shandong Weigao Group Medical Polymer Co to be Significantly Undervalued.

Key valuation signals for SHWGY:

EBIT: $321 Mil
GF Value™: $3.17 vs. price of $1.58 (50.2% below fair value)
GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the SHWGY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Weigao Group Medical Polymer Co Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies HKSE:06699 HKSE:02276 HKSE:01501 HKSE:03600 HKSE:06929 HKSE:01358 HKSE:00876 HKSE:01120 HKSE:00630 HKSE:01134 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Other Exchanges SHWGF:USA 01066:Hong Kong UK2:Germany

Address No.1, Weigao Road, Torch Hi-tech Science Park, Shandong Province, Weihai, CHN

Website https://www.weigaogroup.com

Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.

70GF Score

Get the complete analysis for SHWGY

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.58

Price

$3.17

GF Value

View SHWGY Analysis

See EBIT data for all stocks →